Side O O O O
effects O O O O
during O O O O
the O O O O
week O O O O
after O O O O
first O O O O
dose O O O O
vaccination O O O O
with O O O O
four O O O O
Covid-19 O O O O
vaccines. O O O O
Results O O O O
of O O O O
the O O O O
ProVaVac O O O O
Survey O O O O
Study O O O O
with O O O O
13,837 O O O O
people O O O O
in O O O O
Spain O O O O
- O O O O
PMID: O O O O
36068110 O O O O
- O O O O
PMCID: O O O O
[PMC9420721](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc9420721/) O O O O
- O O O O
DOI: O O O O
[10.1016/j.vaccine.2022.08.028](https://doi.org/10.1016/j.vaccine.2022.08.028) O O O O
Side Reason 3 O O
effects Reason 3 O O
during Reason 3 O O
the Reason 3 O O
week Reason 3 O O
after Reason 3 O O
first Reason 3 O O
dose Reason 3 O O
vaccination Reason 3 O O
with Reason 3 O O
four Reason 3 O O
Covid-19 Reason 3 O O
vaccines. Reason 3 O O
Results Reason 3 O O
of Reason 3 O O
the Reason 3 O O
ProVaVac Reason 3 O O
Survey Reason 3 O O
Study Reason 3 O O
with Reason 3 O O
13,837 Reason 3 O O
people Reason 3 O O
in Reason 3 O O
Spain Reason 3 O O
Abstract Reason 3 O O
Background: Reason 3 O O
In Reason 3 O O
2021, Reason 3 O O
four Reason 3 O O
vaccines Reason 3 O O
against Reason 3 O O
Covid-19 Reason 3 O O
(BNT162b2, Reason 3 O O
mRNA-1273, Reason 3 O O
ChAdOx1nCoV-19, Reason 3 O O
and Reason 3 O O
JNJ-78436735) Reason 3 O O
were Reason 3 O O
employed Reason 3 O O
in Reason 3 O O
the Reason 3 O O
region Reason 3 O O
of Reason 3 O O
Valencia, Reason 3 O O
Spain. Reason 3 O O
We Reason 3 O O
conducted Reason 3 O O
a Reason 3 O O
survey Reason 3 O O
to Reason 3 O O
identify Reason 3 O O
real-world, Reason 3 O O
self-reported Reason 3 O O
frequency Reason 3 O O
and Reason 3 O O
severity Reason 3 O O
of Reason 3 O O
side Reason 3 O O
effects Reason 3 O O
during Reason 3 O O
the Reason 3 O O
week Reason 3 O O
after Reason 3 O O
vaccination. Reason 3 O O
Methods: Reason 3 O O
Survey Reason 3 O O
data Reason 3 O O
was Reason 3 O O
obtained Reason 3 O O
from Reason 3 O O
April Reason 3 O O
19, Reason 3 O O
2021, Reason 3 O O
to Reason 3 O O
October Reason 3 O O
6, Reason 3 O O
2021, Reason 3 O O
at Reason 3 O O
three Reason 3 O O
different Reason 3 O O
moments Reason 3 O O
in Reason 3 O O
time: Reason 3 O O
day Reason 3 O O
one, Reason 3 O O
day Reason 3 O O
three Reason 3 O O
and Reason 3 O O
day Reason 3 O O
seven Reason 3 O O
after Reason 3 O O
vaccination. Reason 3 O O
Answers Reason 3 O O
were Reason 3 O O
linked Reason 3 O O
to Reason 3 O O
individual-level, Reason 3 O O
personal Reason 3 O O
and Reason 3 O O
clinical Reason 3 O O
information. Reason 3 O O
Respondents Reason 3 O O
were Reason 3 O O
stratified Reason 3 O O
by Reason 3 O O
the Reason 3 O O
vaccine Reason 3 O O
they Reason 3 O O
received Reason 3 O O
and Reason 3 O O
reported Reason 3 O O
effects Reason 3 O O
were Reason 3 O O
presented Reason 3 O O
over Reason 3 O O
time Reason 3 O O
and Reason 3 O O
stratified Reason 3 O O
by Reason 3 O O
severity. Reason 3 O O
We Reason 3 O O
compared Reason 3 O O
our Reason 3 O O
results Reason 3 O O
per Reason 3 O O
vaccine Reason 3 O O
with Reason 3 O O
the Reason 3 O O
frequencies Reason 3 O O
stated Reason 3 O O
in Reason 3 O O
each Reason 3 O O
Summary Reason 3 O O
of Reason 3 O O
Product Reason 3 O O
Characteristics Reason 3 O O
(SmPC). Reason 3 O O
We Reason 3 O O
used Reason 3 O O
binomial Reason 3 O O
logistic Reason 3 O O
models Reason 3 O O
to Reason 3 O O
identify Reason 3 O O
associations Reason 3 O O
between Reason 3 O O
respondent Reason 3 O O
characteristics Reason 3 O O
and Reason 3 O O
side Reason 3 O O
effects. Reason 3 O O
Results: Reason 3 O O
No Reason 3 O O
symptoms Reason 3 O O
were Reason 3 O O
reported Reason 3 O O
by Reason 3 O O
1,986 Reason 3 O O
respondents Reason 3 O O
(14.35 Reason 3 O O
%), Reason 3 O O
6,254 Reason 3 O O
informed Reason 3 O O
exclusively Reason 3 O O
mild Reason 3 O O
symptoms Reason 3 O O
(45.20 Reason 3 O O
%), Reason 3 O O
3,444 Reason 3 O O
up Reason 3 O O
to Reason 3 O O
moderate Reason 3 O O
symptoms Reason 3 O O
(24.89 Reason 3 O O
%), Reason 3 O O
and Reason 3 O O
2,153 Reason 3 O O
people Reason 3 O O
(15.56 Reason 3 O O
%) Reason 3 O O
notified Reason 3 O O
also Reason 3 O O
severe Reason 3 O O
symptoms. Reason 3 O O
Among Reason 3 O O
the Reason 3 O O
latter, Reason 3 O O
the Reason 3 O O
more Reason 3 O O
frequent Reason 3 O O
were Reason 3 O O
extreme Reason 3 O O
tiredness Reason 3 O O
(7.0 Reason 3 O O
%), Reason 3 O O
and Reason 3 O O
nausea Reason 3 O O
or Reason 3 O O
vomiting Reason 3 O O
(7.1 Reason 3 O O
%). Reason 3 O O
The Reason 3 O O
reported Reason 3 O O
frequency Reason 3 O O
of Reason 3 O O
facial Reason 3 O O
paralysis Reason 3 O O
(0.4 Reason 3 O O
%) Reason 3 O O
was Reason 3 O O
much Reason 3 O O
higher Reason 3 O O
than Reason 3 O O
reflected Reason 3 O O
in Reason 3 O O
SmPCs. Reason 3 O O
Female Reason 3 O O
sex, Reason 3 O O
younger Reason 3 O O
age, Reason 3 O O
previous Reason 3 O O
positive Reason 3 O O
Active Reason 3 O O
Infection Reason 3 O O
Diagnostic Reason 3 O O
Test, Reason 3 O O
chronicity, Reason 3 O O
and Reason 3 O O
vaccination Reason 3 O O
with Reason 3 O O
other Reason 3 O O
than Reason 3 O O
the Reason 3 O O
BNT162b2 Reason 3 O O
vaccine Reason 3 O O
were Reason 3 O O
associated Reason 3 O O
to Reason 3 O O
an Reason 3 O O
increased Reason 3 O O
risk Reason 3 O O
of Reason 3 O O
side Reason 3 O O
effects Reason 3 O O
(p Reason 3 O O
< Reason 3 O O
0.001). Reason 3 O O
Conclusions: O O O O
Side Reason 4 O O
effects Reason 4 O O
after Reason 4 O O
vaccination Reason 4 O O
are Reason 4 O O
common Reason 4 O O
in Reason 4 O O
the Reason 4 O O
real-world. Reason 4 O O
However, Reason 4 O O
they Reason 4 O O
are Reason 4 O O
principally Reason 4 O O
mild, Reason 4 O O
and Reason 4 O O
their Reason 4 O O
frequency Reason 4 O O
declines Reason 4 O O
after Reason 4 O O
a Reason 4 O O
few Reason 4 O O
days. Reason 4 O O
Providing Reason 4 O O
patients Reason 4 O O
with Reason 4 O O
dependable, Reason 4 O O
beforehand Reason 4 O O
information Reason 4 O O
about Reason 4 O O
side Reason 4 O O
effects Reason 4 O O
may Reason 4 O O
improve Reason 4 O O
outcomes Reason 4 O O
and Reason 4 O O
reinforce Reason 4 O O
vaccination Reason 4 O O
programs. Reason 4 O O
Keywords: O O O O
Covid-19; O O O O
Side O O O O
effects; O O O O
Spain; O O O O
Survey; O O O O
Vaccines. O O O O
Copyright O O O O
Â© O O O O
2022 O O O O
The O O O O
Author(s). O O O O
Published O O O O
by O O O O
Elsevier O O O O
Ltd.. O O O O
All O O O O
rights O O O O
reserved. O O O O
Conflict O O O O
of O O O O
interest O O O O
statement O O O O
Declaration O O O O
of O O O O
Competing O O O O
Interest O O O O
The O O O O
authors O O O O
declare O O O O
that O O O O
they O O O O
have O O O O
no O O O O
known O O O O
competing O O O O
financial O O O O
interests O O O O
or O O O O
personal O O O O
relationships O O O O
that O O O O
could O O O O
have O O O O
appeared O O O O
to O O O O
influence O O O O
the O O O O
work O O O O
reported O O O O
in O O O O
this O O O O
paper. O O O O
Figures O O O O
Similar O O O O
articles O O O O
- O O O O
[Risk O O O O
of O O O O
thrombocytopenia O O O O
and O O O O
thromboembolism O O O O
after O O O O
covid-19 O O O O
vaccination O O O O
and O O O O
[Adverse O O O O
events O O O O
following O O O O
COVID-19 O O O O
vaccination O O O O
in O O O O
South O O O O
Korea O O O O
between O O O O
February O O O O
28 O O O O
and O O O O
August O O O O
21, O O O O
2021: O O O O
A O O O O
nationwide O O O O
observational O O O O
study.](/35276381/)Int O O O O
J O O O O
Infect O O O O
Dis. O O O O
2022 O O O O
May;118:173-182. O O O O
doi: O O O O
10.1016/j.ijid.2022.03.007. O O O O
PMID: O O O O
35276381 O O O O
Free O O O O
PMC O O O O
article. O O O O
- O O O O
[Acute O O O O
reactions O O O O
after O O O O
a O O O O
homologous O O O O
primary O O O O
COVID-19 O O O O
vaccination O O O O
series: O O O O
Analysis O O O O
of O O O O
Taiwan O O O O
V-Watch O O O O
data.](/37029003/)Vaccine. O O O O
2023 O O O O
Apr O O O O
24;41(17):2853-2859. O O O O
Free O O O O
PMC O O O O
article. O O O O
- O O O O
[MOG O O O O
encephalomyelitis O O O O
after O O O O
vaccination O O O O
against O O O O
severe O O O O
acute O O O O
respiratory O O O O
syndrome O O O O
coronavirus O O O O
type O O O O
2 O O O O
(SARS-CoV-2): O O O O
case O O O O
report O O O O
and O O O O
comprehensive O O O O
article. O O O O
Review. O O O O
- O O O O
[Longevity O O O O
of O O O O
immunity O O O O
following O O O O
COVID-19 O O O O
vaccination: O O O O
a O O O O
comprehensive O O O O
review O O O O
of O O O O
the O O O O
currently O O O O
PMC O O O O
article. O O O O
Review. O O O O
Cited O O O O
by O O O O
- O O O O
[Side O O O O
Effects O O O O
of O O O O
COVID-19 O O O O
Vaccines O O O O
in O O O O
Pregnant O O O O
and O O O O
Lactating O O O O
Mexican O O O O
Women O O O O
and O O O O
Breastfed O O O O
Infants: O O O O
A O O O O
Survey-Based O O O O
Study.](/37631848/)Vaccines O O O O
- O O O O
[Heterologous O O O O
Vector-mRNA O O O O
Based O O O O
SARS-CoV-2 O O O O
Vaccination O O O O
Strategy O O O O
Appears O O O O
Superior O O O O
to O O O O
a O O O O
Homologous O O O O
Vector-Based O O O O
Vaccination O O O O
Scheme O O O O
in O O O O
German O O O O
Healthcare O O O O
Workers O O O O
Regarding O O O O
Humoral O O O O
SARS-CoV-2 O O O O
Response O O O O
Indicating O O O O
a O O O O
High O O O O
Boosting O O O O
Effect O O O O
by O O O O
mRNA O O O O
Vaccines.](/36992285/)Vaccines O O O O
(Basel). O O O O
2023 O O O O
Mar O O O O
19;11(3):701. O O O O
doi: O O O O
10.3390/vaccines11030701. O O O O
Vaccines O O O O
(Basel). O O O O
2023. O O O O
PMID: O O O O
36992285 O O O O
Free O O O O
PMC O O O O
article. O O O O
References O O O O
- O O O O
- O O O O
European O O O O
Medicines O O O O
Agency. O O O O
Covid-19 O O O O
vaccines: O O O O
authorized. O O O O
Available O O O O
in: O O O O
[https://www.ema.europa.eu/en/human-regulatory/overview/public-health-thr...](https://www.ema.europa.eu/en/human-regulatory/overview/public-health-threats/coronavirus-disease-Covid-19/treatments-vaccines/vaccines-Covid-19/Covid-19-vaccines-authorised%23authorised-Covid-19-vaccines-section)[accessed: O O O O
October O O O O
18, O O O O
2021]. O O O O
- O O O O
European O O O O
Medicines O O O O
Agency. O O O O
Covid-19 O O O O
vaccines: O O O O
authorized. O O O O
Available O O O O
in: O O O O
- O O O O
- O O O O
Riad O O O O
S., O O O O
Perii O O O O
T.P., O O O O
uljevi O O O O
M.F., O O O O
JÃ¼risson O O O O
M., O O O O
et O O O O
al. O O O O
Covid-19 O O O O
Vaccines O O O O
Safety O O O O
Tracking O O O O
(CoVaST): O O O O
Protocol O O O O
of O O O O
a O O O O
Multi-Center O O O O
Prospective O O O O
Cohort O O O O
Study O O O O
for O O O O
Active O O O O
Surveillance O O O O
of O O O O
Covid-19 O O O O
Vaccines' O O O O
Side O O O O
Effects. O O O O
Int O O O O
J O O O O
Environ O O O O
Res O O O O
Public O O O O
Health. O O O O
2021;18(15):7859. O O O O
- O O O O
[PMC](http://www.ncbi.nlm.nih.gov/pmc/articles/pmc8345554/)- O O O O
[PubMed](/34360156/) O O O O
uljevi O O O O
M.F., O O O O
JÃ¼risson O O O O
M., O O O O
et O O O O
al. O O O O
Covid-19 O O O O
Vaccines O O O O
Safety O O O O
Tracking O O O O
(CoVaST): O O O O
Protocol O O O O
of O O O O
a O O O O
Multi-Center O O O O
Prospective O O O O
Cohort O O O O
Study O O O O
for O O O O
Active O O O O
Surveillance O O O O
of O O O O
Covid-19 O O O O
Vaccines' O O O O
Side O O O O
Effects. O O O O
Int O O O O
J O O O O
Environ O O O O
Res O O O O
Public O O O O
Health. O O O O
2021;18(15):7859. O O O O
- O O O O
- O O O O
- O O O O
Centers O O O O
for O O O O
Disease O O O O
Control O O O O
and O O O O
Prevention. O O O O
V-safe O O O O
protocol: O O O O
version O O O O
3; O O O O
2021. O O O O
Available O O O O
in: O O O O
[https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-508.pdf](https://www.cdc.gov/vaccinesafety/pdf/V-safe-Protocol-508.pdf)[accessed: O O O O
Sept O O O O
4, O O O O
- O O O O
Centers O O O O
Disease O O O O
Control O O O O
and O O O O
Prevention. O O O O
V-safe O O O O
protocol: O O O O
version O O O O
3; O O O O
2021. O O O O
Available O O O O
in: O O O O
- O O O O
- O O O O
Publication O O O O
types O O O O
MeSH O O O O
terms O O O O
Substances O O O O
LinkOut O O O O
- O O O O
more O O O O
resources O O O O
Full O O O O
Text O O O O
Sources O O O O
Medical O O O O
Miscellaneous O O O O
